Literature DB >> 25467110

Beyond BRCA: new hereditary breast cancer susceptibility genes.

P Economopoulou1, G Dimitriadis2, A Psyrri2.   

Abstract

Approximately 5-10% of breast cancer cases might be inheritable, up to 30% of which are due to BRCA1/2 mutations. During the past few years and thanks to technology evolution, we have been witnesses of an intensive search of additional genes with similar characteristics, under the premise that successful gene discovery will provide substantial opportunities for primary and secondary prevention of breast cancer. Consequently, new genes have emerged as breast cancer susceptibility genes, including rare germline mutations in high penetrant genes, such as TP53 and PTEN, and more frequent mutations in moderate penetrant genes, such as CHEK2, ATM and PALB2. This review will summarize current data on new findings in breast cancer susceptibility genes.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer susceptibility genes; Hereditary breast cancer; PALB2; PTEN; TP53

Mesh:

Substances:

Year:  2014        PMID: 25467110     DOI: 10.1016/j.ctrv.2014.10.008

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  64 in total

1.  Association of HLA-G +3142 C>G polymorphism and breast cancer in Tunisian population.

Authors:  Inès Zidi; Olfa Dziri; Nour Zidi; Refaat Sebai; Nadia Boujelebene; Amna Ben Hassine; Hamza Ben Yahia; Ahmed Baligh Laaribi; Wafa Babay; Hela Rifi; Amel Mezlini; Hanene Chelbi
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

Review 2.  Role of MicroRNA Regulation in Obesity-Associated Breast Cancer: Nutritional Perspectives.

Authors:  Ravi Kasiappan; Dheeran Rajarajan
Journal:  Adv Nutr       Date:  2017-11-15       Impact factor: 8.701

3.  Inference for survival prediction under the regularized Cox model.

Authors:  Jennifer A Sinnott; Tianxi Cai
Journal:  Biostatistics       Date:  2016-04-22       Impact factor: 5.899

4.  Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.

Authors:  Bryce A Seifert; Julianne M O'Daniel; Krunal Amin; Daniel S Marchuk; Nirali M Patel; Joel S Parker; Alan P Hoyle; Lisle E Mose; Andrew Marron; Michele C Hayward; Christopher Bizon; Kirk C Wilhelmsen; James P Evans; H Shelton Earp; Norman E Sharpless; D Neil Hayes; Jonathan S Berg
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

5.  Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study.

Authors:  Amandine I Garcia; Monique Buisson; Francesca Damiola; Chloé Tessereau; Laure Barjhoux; Carole Verny-Pierre; Valérie Sornin; Marie-Gabrielle Dondon; Séverine Eon-Marchais; Olivier Caron; Marion Gautier-Villars; Isabelle Coupier; Bruno Buecher; Philippe Vennin; Muriel Belotti; Alain Lortholary; Paul Gesta; Catherine Dugast; Catherine Noguès; Jean-Pierre Fricker; Laurence Faivre; Dominique Stoppa-Lyonnet; Nadine Andrieu; Olga M Sinilnikova; Sylvie Mazoyer
Journal:  Eur J Hum Genet       Date:  2016-01-20       Impact factor: 4.246

6.  Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey.

Authors:  G Cecener; G Guney Eskiler; U Egeli; B Tunca; A Alemdar; S Gokgoz; I Tasdelen
Journal:  Mol Biol Rep       Date:  2016-08-29       Impact factor: 2.316

7.  Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.

Authors:  P Riedlova; J Janoutova; B Hermanova
Journal:  Mol Biol Rep       Date:  2020-03-16       Impact factor: 2.316

8.  Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes.

Authors:  Yoshiaki Shinden; Tadahiro Hirashima; Nijiro Nohata; Hiroko Toda; Reona Okada; Shunichi Asai; Takako Tanaka; Yuto Hozaka; Takao Ohtsuka; Yuko Kijima; Naohiko Seki
Journal:  J Hum Genet       Date:  2020-11-12       Impact factor: 3.172

9.  Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.

Authors:  Kutluk H Oktay; Giuliano Bedoschi; Shari B Goldfarb; Enes Taylan; Shiny Titus; Glenn E Palomaki; Tessa Cigler; Mark Robson; Maura N Dickler
Journal:  Fertil Steril       Date:  2020-04-22       Impact factor: 7.329

Review 10.  Update on PARP Inhibitors in Breast Cancer.

Authors:  Alexandra S Zimmer; Mitchell Gillard; Stanley Lipkowitz; Jung-Min Lee
Journal:  Curr Treat Options Oncol       Date:  2018-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.